Literature DB >> 24188018

Developing bivalent ligands to target CUG triplet repeats, the causative agent of myotonic dystrophy type 1.

Yuan Fu1, Kali A Miller1, Lien Nguyen1, Amin Haghighat Jahromi2,1, Long M Luu1, Anne M Baranger1, Steven C Zimmerman2,1.   

Abstract

An expanded CUG repeat transcript (CUG(exp)) is the causative agent of myotonic dystrophy type 1 (DM1) by sequestering muscleblind-like 1 protein (MBNL1), a regulator of alternative splicing. On the basis of a ligand (1) that was previously reported to be active in an in vitro assay, we present the synthesis of a small library containing 10 dimeric ligands (4-13) that differ in length, composition, and attachment point of the linking chain. The oligoamino linkers gave a greater gain in affinity for CUG RNA and were more effective when compared to oligoether linkers. The most potent in vitro ligand (9) was shown to be aqueous-soluble and both cell- and nucleus-permeable, displaying almost complete dispersion of MBNL1 ribonuclear foci in a DM1 cell model. Direct evidence for the bioactivity of 9 was observed in its ability to disperse ribonuclear foci in individual live DM1 model cells using time-lapse confocal fluorescence microscopy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24188018      PMCID: PMC3925341          DOI: 10.1021/jm400794z

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  64 in total

Review 1.  Mechanisms of RNA-mediated disease.

Authors:  Jason R O'Rourke; Maurice S Swanson
Journal:  J Biol Chem       Date:  2008-10-28       Impact factor: 5.157

2.  The influence of rigid or flexible linkage between two ligands on the effective affinity and avidity for reversible interactions with bivalent receptors.

Authors:  S A Bobrovnik
Journal:  J Mol Recognit       Date:  2007 Jul-Aug       Impact factor: 2.137

Review 3.  Molecular therapy in myotonic dystrophy: focus on RNA gain-of-function.

Authors:  Susan A M Mulders; Baziel G M van Engelen; Bé Wieringa; Derick G Wansink
Journal:  Hum Mol Genet       Date:  2010-04-20       Impact factor: 6.150

4.  Bivalent dopamine D2 receptor ligands: synthesis and binding properties.

Authors:  Julia Kühhorn; Harald Hübner; Peter Gmeiner
Journal:  J Med Chem       Date:  2011-06-03       Impact factor: 7.446

5.  Development of a bivalent dopamine D₂ receptor agonist.

Authors:  Julia Kühhorn; Angela Götz; Harald Hübner; Dawn Thompson; Jennifer Whistler; Peter Gmeiner
Journal:  J Med Chem       Date:  2011-10-31       Impact factor: 7.446

Review 6.  Pathogenic mechanisms of myotonic dystrophy.

Authors:  Johanna E Lee; Thomas A Cooper
Journal:  Biochem Soc Trans       Date:  2009-12       Impact factor: 5.407

7.  Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA.

Authors:  Thurman M Wheeler; Krzysztof Sobczak; John D Lueck; Robert J Osborne; Xiaoyan Lin; Robert T Dirksen; Charles A Thornton
Journal:  Science       Date:  2009-07-17       Impact factor: 47.728

8.  Pentamidine reverses the splicing defects associated with myotonic dystrophy.

Authors:  M Bryan Warf; Masayuki Nakamori; Catherine M Matthys; Charles A Thornton; J Andrew Berglund
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-12       Impact factor: 11.205

9.  Rational design of ligands targeting triplet repeating transcripts that cause RNA dominant disease: application to myotonic muscular dystrophy type 1 and spinocerebellar ataxia type 3.

Authors:  Alexei Pushechnikov; Melissa M Lee; Jessica L Childs-Disney; Krzysztof Sobczak; Jonathan M French; Charles A Thornton; Matthew D Disney
Journal:  J Am Chem Soc       Date:  2009-07-22       Impact factor: 15.419

10.  From dynamic combinatorial 'hit' to lead: in vitro and in vivo activity of compounds targeting the pathogenic RNAs that cause myotonic dystrophy.

Authors:  Leslie O Ofori; Jason Hoskins; Masayuki Nakamori; Charles A Thornton; Benjamin L Miller
Journal:  Nucleic Acids Res       Date:  2012-04-06       Impact factor: 16.971

View more
  31 in total

1.  A Potent Inhibitor of Protein Sequestration by Expanded Triplet (CUG) Repeats that Shows Phenotypic Improvements in a Drosophila Model of Myotonic Dystrophy.

Authors:  Long M Luu; Lien Nguyen; Shaohong Peng; JuYeon Lee; Hyang Yeon Lee; Chun-Ho Wong; Paul J Hergenrother; H Y Edwin Chan; Steven C Zimmerman
Journal:  ChemMedChem       Date:  2016-06-01       Impact factor: 3.466

2.  Development of novel macrocyclic small molecules that target CTG trinucleotide repeats.

Authors:  Julio F Serrano; JuYeon Lee; L Daniel Curet; Lauren D Hagler; Sarah E Bonson; Emma J Schuster; Steven C Zimmerman
Journal:  Bioorg Med Chem       Date:  2019-05-14       Impact factor: 3.641

3.  Intrinsically cell-penetrating multivalent and multitargeting ligands for myotonic dystrophy type 1.

Authors:  JuYeon Lee; Yugang Bai; Ullas V Chembazhi; Shaohong Peng; Kevin Yum; Long M Luu; Lauren D Hagler; Julio F Serrano; H Y Edwin Chan; Auinash Kalsotra; Steven C Zimmerman
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-11       Impact factor: 11.205

Review 4.  Design of small molecules targeting RNA structure from sequence.

Authors:  Andrei Ursu; Jessica L Childs-Disney; Ryan J Andrews; Collin A O'Leary; Samantha M Meyer; Alicia J Angelbello; Walter N Moss; Matthew D Disney
Journal:  Chem Soc Rev       Date:  2020-10-19       Impact factor: 54.564

Review 5.  Structure based approaches for targeting non-coding RNAs with small molecules.

Authors:  Matthew D Shortridge; Gabriele Varani
Journal:  Curr Opin Struct Biol       Date:  2015-02-16       Impact factor: 6.809

Review 6.  Modeling ALS and FTD with iPSC-derived neurons.

Authors:  Sebum Lee; Eric J Huang
Journal:  Brain Res       Date:  2015-10-14       Impact factor: 3.252

7.  S-phase Enriched Non-coding RNAs Regulate Gene Expression and Cell Cycle Progression.

Authors:  Ozlem Yildirim; Enver C Izgu; Manashree Damle; Vladislava Chalei; Fei Ji; Ruslan I Sadreyev; Jack W Szostak; Robert E Kingston
Journal:  Cell Rep       Date:  2020-05-12       Impact factor: 9.423

8.  Lomofungin and dilomofungin: inhibitors of MBNL1-CUG RNA binding with distinct cellular effects.

Authors:  Jason W Hoskins; Leslie O Ofori; Catherine Z Chen; Amit Kumar; Krzysztof Sobczak; Masayuki Nakamori; Noel Southall; Samarjit Patnaik; Juan J Marugan; Wei Zheng; Christopher P Austin; Matthew D Disney; Benjamin L Miller; Charles A Thornton
Journal:  Nucleic Acids Res       Date:  2014-05-05       Impact factor: 16.971

Review 9.  Targeting RNA in mammalian systems with small molecules.

Authors:  Anita Donlic; Amanda E Hargrove
Journal:  Wiley Interdiscip Rev RNA       Date:  2018-05-03       Impact factor: 9.957

10.  Small molecules that target the toxic RNA in myotonic dystrophy type 2.

Authors:  Lien Nguyen; JuYeon Lee; Chun-Ho Wong; Steven C Zimmerman
Journal:  ChemMedChem       Date:  2014-06-17       Impact factor: 3.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.